LabGenius

Company profile

About LabGenius

LabGenius Therapeutics is a biotechnology company that has developed the EVA™ platform, a highly automated discovery engine that enables the rapid identification and co-optimisation of complex therapeutic antibodies across multiple key properties. The company combines human and machine intelligence to address the challenge that molecule performance is governed by a complex interplay of factors, making complex antibodies like multispecifics hard to engineer using conventional methods. LabGenius's platform is both modality and format-agnostic, but for its internal pipeline, the company focuses on the development of selectivity-enhanced antibodies for the treatment of solid tumours. The EVA™ platform tightly integrates machine learning with automated functional screening in a closed loop, using proprietary ML-grade data from both functional and developability assays to fuel Multi-Objective Bayesian Optimisation. This approach enables the company to rapidly evaluate large numbers of multispecifics (>100,000 designs) for both function and developability, with each design-build-test-learn cycle taking less than 6 weeks. The platform can work with any modality including T-cell engagers, ADCs, NK-cell engagers, TCR-based engagers, agonists, cell therapies, radioconjugates, and multispecifics. LabGenius has raised over $75 million from top-tier venture capital firms and has established R&D partnerships with leading pharmaceutical companies including LG Chem.

Company description · LabGenius official website